Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success of anti-CD19 chimeric antigen receptor (CAR) T cell therapies against B-lineage malignancies, many studies have attempted to translate the success of CAR T cell therapy to other malignancies, including AML. This review summarizes the current advances in CAR T cell therapy against AML, including preclinical studies and clinical trials, and discusses the potential AML-associated surface markers that could be used for further CAR technology. Finally, we describe strategies that might address the current issues of employing CAR T cell therapy in AML.

This review is likely to enable a detailed insight on nanocrystal technology as a strategy to improve drug bioavailability and antitumor efficacy for the cancer treatment and be of particular interest to pharmaceutical industry.

Hydrotropic polymer-based paclitaxel-loaded self-assembled nanoparticles: preparation and biological evaluation.

No abstract